92,800 Shares in NeuroDerm Ltd. (NDRM) Acquired by C WorldWide Group Holding A S

C WorldWide Group Holding A S purchased a new position in NeuroDerm Ltd. (NASDAQ:NDRM) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 92,800 shares of the biotechnology company’s stock, valued at approximately $2,775,000.

Several other hedge funds have also recently modified their holdings of the company. OppenheimerFunds Inc. bought a new position in shares of NeuroDerm during the first quarter valued at approximately $7,588,000. Renaissance Technologies LLC bought a new position in shares of NeuroDerm during the fourth quarter valued at approximately $1,797,000. Bailard Inc. increased its position in shares of NeuroDerm by 9.5% in the first quarter. Bailard Inc. now owns 109,000 shares of the biotechnology company’s stock valued at $2,894,000 after buying an additional 9,500 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of NeuroDerm during the first quarter valued at approximately $242,000. Finally, Bank of Montreal Can bought a new position in shares of NeuroDerm during the first quarter valued at approximately $266,000. 52.82% of the stock is owned by institutional investors.

NeuroDerm Ltd. (NASDAQ:NDRM) opened at 38.60 on Friday. The stock’s 50 day moving average is $33.65 and its 200 day moving average is $27.49. The company’s market cap is $1.02 billion. NeuroDerm Ltd. has a 1-year low of $15.20 and a 1-year high of $38.85.

NeuroDerm (NASDAQ:NDRM) last released its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.13. Equities analysts anticipate that NeuroDerm Ltd. will post ($2.03) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/12/92800-shares-in-neuroderm-ltd-ndrm-acquired-by-c-worldwide-group-holding-a-s.html.

NDRM has been the subject of several research reports. Deutsche Bank AG initiated coverage on shares of NeuroDerm in a research note on Friday, July 21st. They issued a “buy” rating and a $47.00 price objective for the company. Roth Capital set a $33.00 price objective on shares of NeuroDerm and gave the company a “buy” rating in a research note on Wednesday, June 14th. Jefferies Group LLC reissued a “buy” rating and issued a $42.00 price objective on shares of NeuroDerm in a research note on Monday, April 24th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of NeuroDerm in a research note on Sunday, May 14th. Finally, BidaskClub raised shares of NeuroDerm from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $44.13.

NeuroDerm Company Profile

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Want to see what other hedge funds are holding NDRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeuroDerm Ltd. (NASDAQ:NDRM).

Institutional Ownership by Quarter for NeuroDerm (NASDAQ:NDRM)

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply